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ABSTRACT 
Objective: Docking studies of aminohydantoin derivatives as antimalarial agents. A novel derivative of aminohydantoins was 
selected from the literature. Method: in-silco studies using docking methodology. The compounds were sketched and energy 
minimized using Chem draw ultra and Chem 3D ultra respectively. Further, the compounds were docked into Plasmodium 
falciparum transferase inhibitor (3L7) using Molegro Virtual Platform. Twenty eight compounds were docked into the active site of 
Pf-lactate dehydrogenase cavity and all of them found to have similar binding interactions of a co-crystalized ligand. Result: The 
compounds were showed good docking score like moldock score and re-rank score. The finding of docking studies shows a typical 
molecular interaction pattern with lactate dehydrogenase. The binding interaction information derived from these molecules will be 
useful in future antimalarial agent design. Conclusion: From the docking study, it was observed that ligands bind to the electrostatic, 
hydrophobic clamp formed by the residues Asp 76(B), Tyr 190(B), Tyr 80(B) and Lys 72(B) which play an important role for 
Plasmodium falciparum inhibition.   The binding affinity, grid calculation and RMSD percentage lower and upper   parameters were 
calculated.   Hence, the observable data indicated that, above compounds can serve as good leads for further modification and 
optimization in the of treatment malaria. 
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Malarial is a tropical parasitic disease caused by 
protozoa belonging to the genus Plasmodium 
falciparum. It occurs majorly in temperate regions and it 
also present globally due to climate change. Sub-
Saharan Africa carries a disproportionately high share of 
the global malaria burden. In 2016, the region was home 
to 89% of malaria cases and 91% of malaria deaths. P. 
falciparum is the most prevalent malaria parasite on the 
African continent.
1-10
 According to the latest WHO 
estimates, released in 2015, there were 216 million cases 
of malaria in 2016 and 445000 deaths. Some countries – 
mainly in sub-Saharan Africa – account for 90% of 
malaria cases and 78% deaths globally. In earlier 2000, 
the decrease in malaria prevalence in these 15 countries 
(32%) has straggle back that of other countries 
worldwide (54%). In areas with giant transferral of 
malaria, juvenile beneath 5 are extremely vulnerable to 
inflammation, sickness and demise; additional than two 
thirds (70%) of all malaria demises occur in this age 
group. Between 2000 and 2015, the under-5 malaria 
death rate fell by 65% globally, translating into an 
estimated 5.9 million child lives saved.
11
 Molecular 
Docking is well established computational technique 
which predicts the interaction energy between two 
molecules and to find the best orientation of ligand 
which would form a complex with overall minimum 
energy.
12
 The small molecule, known as ligand normally 
lay within protein’s cavity which is anticipate by the 
explore algorithm. These protein cavities overtake vital 
when they come in exposure with any external 
compounds and are consequently called as energetic 
sites. The molecular docking approach can be used to 
model the interaction between a small molecule and a 
protein at the atomic level, which permit us to 
distinguish the behaviour of small molecules in the 
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binding site of desire proteins as well as to illuminate 
basic biochemical processes.
13
 The docking process 
involves two basic steps: prediction of the ligand 
conformation as well as its position and orientation 
within these sites (usually referred to as poses) and 
assessment of the binding affinity.
14
 These two steps are 
related to sampling methods and scoring schemes, 
respectively, which will be discussed in the theory 
section. The docking studies are normally employed to 
augur the binding direction of molecule to resident 
protein targets in concatenation to envisage the affinity 
and action of the molecule. Therefore docking plays a 
dominant key position in the rational drug design. 
Molegro virtual docker is an discriminatory programme 
for predicting- ligand interactions. MVD requires a 3d 
structures of both protein and ligand routinely acquire 
from x-ray /NMR demonstration or homology 
modelling. MVD execute flexible ligand docking, so the 
optimal calculation of the ligand will be purposive 
through the docking. MVD supervise all appearance of 
the docking procedure from construction of the 
molecules to determine of the probable binding sites, of 
the target protein and projection of the binding modes of 
the ligand. MVD suggest high quality docking based 
bases on a moves optimization techniques combined 
with a user interface experience focusing on usability 
and productivity.
15-17 
MATERIALS & METHODS 
The software Chemdraw Ultra ver. 8.0 and Molegro 
virtual Docker ver. 6.0 were used for docking studies. 
Protein primary sequence and structure retrieval   
The three-dimensional x-ray crystallography structures 
of aminohydantoins, (PDB ID: 4RAO) were obtained 
from Protein Data Bank (www. rcsb.org), which is a 
single worldwide archive of structural data of biological 
macromolecules.
18-19 
Ligand   construction 
All the ligands are reported in the research of M. J. 
Marvin et al., on aminohydantion derivatives are sketch 
in chemdraw ultra 2d 8.0 and these structure are 
converted into the 3d using chemdraw ultra 8.0 now 
these structures are energy minimize to 0.01 iteration 
using Mopac grid now these structures are saved in the 
format of dot mol.
20-21
 Docking studies is a type of 
computational approach used to study the Ligand- 
Enzyme interactions which are crucial for activity. The 
study would help to observe the binding fashion of 
compounds with enzyme’s amino acids. Docking 
analysis of all 28 compounds were performed to explore 
the binging of compounds to the important amino acids 
responsible for antimalarial activity. In accordance with 
the targeted enzyme Pdb code- 4RAO was selected for 
antimalarial docking studies of the compounds. 
Validation of Molegro virtual Docker 6.0 is important 
because it is a computational approach, the result may 
be deviate on changing the software.
22
 
As we know that each PDB has its own co-crystalize 
ligand on its active site. In the process of software 
validation we just re-docked that co-crystalize ligand 
with its PDB and observe the orientation and 
conformational changes on it. This will help to stabilize 
the software’s repeatability and validate it.  
Antimalarial docking 
Molecular docking study showed the interaction 
between aminohydantion derivatives and active site of 
protein taken from transferase enzyme (Pdb code- 
4RAO). MolDock Score and MolDock Rerank Score of 
most active compound to that of reference ligand reveals 
the efficient docking interactions of the compound. Asp-
76(B), Try-190(B), Leu-77(B), Thr-45(B), His-38(B), 
Gly-39(B), Asp-43(A), Tyr-80(B) and Met-42(B) are 
the major amino acid bindings responsible for biological 
activity. Among the reference ligand and compounds 
1,9,18,19,26,27 and 28 of these amino acids bindings 
are in common which proves that the binding of the 
compounds takes place with the desired amino acids in 
the protein. Molecular docking scores and data also 
correlate and reconfirm the assumption regarding the 
design and development of new molecules.
23-24 
RESULT AND DISCUSSION  
Docking analysis is important to study the ligand-
enzyme interaction. For the docking analysis, the 
compounds were chosen based on their previously 
evaluated for antimalarial activity. Docking was carried 
out using PDB code 4RAO, using Molegro Virtual 
Docker 6.0. 
PDB Description:  
Name: 4RAO  
Classification: Transferase/ Transferase Inhibitor.  
Organism: Homo sapiens  
Expression System: Escherichia coli 
PDB Ligand: 3L7 
IUPAC:(2-{[2-(6-oxo-1,6-dihydro-9H-purin-9-
yl)ethyl](2{[(E)2 phosphonoethenyl] oxy} ethyl) 
amino}ethyl) phosphonic acid. 
Molecular Formula: C13H21N5O8P2 
Pose analysis of docking of standard drug chloroquine 
and co-crystallized ligand (3L7) explore the common 
amino acid interaction like: Met-42(B), Leu-77(B), Thr-
45(B), Asp-76(B), Tyr-190(B), His-38(B), Gly-39(B), 
Asp-43(A) and Tyr-80(B) which are considered to be 
the active amino acids important for binding of ligand 
on active site. Compound-1 exhibit common binding 
interaction like: Met-42(B), Asp-76(B), Try-190(B), 
Leu-77(B), Thr-45(B), Gly-39(B), His-38(B), Asp-
43(A) and Tyr-80(B) to that of standard active amino 
acids.Compound-9 exhibit common binding interaction 
Met-42(B), Asp-76(B), His-38(B), Try-190(B), Leu-
77(B), Thr-45(B) and Tyr-80(B) with amino acids 
responsible for activity. Compound-18 has common 
binding interactions Met-42(B), Asp-76(B), Try-190(B), 
Asp-79(D), His-38(B) and Asp-43(A) with amino acids. 
Compound-19 exhibit binding with essential amino 
acids like: Met-42(B), Asp-76(B), Try-190(B), Thr-
45(B), Asp-76(B), Gly-39(B), His-38(B) and Asp-
43(A).Compound-26 exhibit binding with Asp-76(B), 
Try-190(B), Leu-77(B), Thr-45(B), Gly-39(B), His-
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38(B), Tyr-80(B) and Asp-43(A).Compound-27 exhibit 
common amino acid bindings with Asp-76(B), Try-
190(B), Leu-77(B), Thr-45(B), Gly-39(B), His-38(B) 
and Asp-43(A). Compound-28 exhibit common amino 
acid bindings with Asp-76(B), Try-190(B), Leu-77(B), 
Thr-45(B), Gly-39(B), His-38(B) and Asp-43(A). 
Computer aided drug designing (CADD) helps the 
researcher to decrease the time and money for drug 
designing projects Molecular docking is very helpful in 
studying the interactions of ligand molecules with the 
target protein before its in vitro synthesis. Docking is 
performed through computer programs like Autodock , 
arguslab and discovery studio3.1.
25-26
 All these 
molecules were taken from ligand database or draw with 
help of  chemical organizer(draw)  software like  
chemdraw ultra 2d & 3d  in mol or pdb format and were 
stored in a database of MOE in mdb format or Pubchem 
database.  All these molecules were docked against the 
same pocket where reference drug bound. Molecules 
were selected from a library of molecules and were 
further assessed by the interaction analysis. Finalized 
molecules showed the interactions with the active 
residue and with other residues.
27 
 
Table 1: Docking Scores of reported compounds (Pdb-4RAO) 
Compound No. Mol Dock Score Re-rank Score H-Bond 
01 -131.531 -78.5204 -3.10212 
02 -103.249 -75.8402 -0.384916 
03 -101.301 -68.5639 -0.752536 
04 -113.662 -87.5361 -2.37363 
05 -113.777 -90.9875 -1.40004 
06 -115.143 -94.3147 - 
07 -110.555 -85.7039 -0.00511253 
08 -102.064 -65.8804 -1.97476 
09 -219.323 -161.412 -0.159418 
10 -100.391 -58.364 0.199877 
11 -97.2375 -57.0105 -0.383658 
12 -102.768 -81.1365 - 
13 -100.765 -58.0613 -0.516466 
14 -98.8683 -72.2189 - 
15 -100.875 -61.7457 0.351308 
16 -100.477 -59.5785 -1.33243 
17 -97.9958 -74.6467 -1.65333 
18 -133.322 -60.3441 -0.914538 
19 -131.747 -96.0003 -0.258545 
20 -105.738 -25.2223 -0.0212229 
21 -116.014 -80.3198 -0.244676 
22 -140.886 -106.217 -1.56805 
23 -118.095 -80.9378 -0.452932 
24 -119.617 -78.4913 -2.5 
25 -175.065 -121.149 -1.37088 
26 -178.584 -121.801 -2.41728 
27 -169.936 -133.218 - 
28 -152.656 -94.752 -4.26752 
 
      
Figure 1: Docking view of all compounds                   Figure 2: Docking pose of compound 1 
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Figure 3: Docking pose of compound 9                      Figure 4: Docking pose of compound 18 
     
Figure 5: Docking pose of compound 19                    Figure 6: Docking pose of compound 26 
      
Figure 7: Docking pose of compound 27                     Figure 8: Docking pose of compound 28 
 
CONCLUSION 
From the present study concluded that the synthesize 
derivatives of aminohydantoin,  showed the good 
docking score and more stable bonding with the 
Plasmodium falciparum so it can be said that, these 
derivatives may be significant against Plasmodium 
falciparum inhibitor. Further study will need to be 
conducted for other properties of drug like, absorption 
metabolism and excretion in human body. On the basis 
of comparison with standard drugs like chloroquine and 
other derivatives selected in this study, which have less 
docking score as compared to the standard. It can be 
concluded that these seven derivatives have good RMSD 
limit so it was made virtual derivatives in these 
molecules could be used as promising inhibitor of 
Plasmodium falciparum to therapeutic value for various 
types of malaria in future. 
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